PGNY Stock Analysis: Buy, Sell, or Hold?
PGNY - Progyny, Inc. Common Stock
$26.89
0.26 (0.98%)
▲
5d:
+1.09%
30d:
+8.08%
90d:
+48.98%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PGNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PGNY shows positive signals but monitor for confirmation. Market pricing in 3.9% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: PGNY shows positive signals but monitor for confirmation. Market pricing in 3.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$31.57
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$19.60
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PGNY is currently trading at $26.89, which is considered slightly high relative to its 30-day fair value range of $24.49 to $26.40. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.2) compared to its historical average (10.9). At these levels, the market is pricing in 3.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PGNY is showing sideways momentum. The price is approaching resistance at $26.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PGNY is showing sideways momentum. The price is approaching resistance at $26.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$24.49 -
$26.40
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($30.00)
- NEUTRAL: Market pricing in 3.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$24.49 -
$26.40
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$24.55
Resistance Level
$26.43
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.19
Wall Street Target
$30.00
(+11.6%)
Revenue Growth (YoY)
1.4%
Earnings Growth (YoY)
70.6%
Profit Margin
5.2%
Valuation Premium vs History
+3.9% premium
PE vs Historical
12.2 vs 10.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.9%
(market-implied from PE analysis)
1-Year Target
$27.94
(+4%)
2-Year Target
$29.03
(+8%)
3-Year Target
$30.16
(+12%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$26.97
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.2%)
$59.16
(+120%)
Base:
(SPY PE: 12.2, Growth: 7.2%)
$33.10
(+23%)
Bear:
(PE: 10.4, Growth: 7.2%)
$28.14
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 34.58 | Current EPS (TTM): $0.77
Bull Case
$58.59
(+118%)
Analyst growth 100.0%, PE expands to 38.0
Base Case
$53.26
(+98%)
Market implied 100.0%, PE stable at 34.6
Bear Case
$18.11
(-33%)
Severe decline -20.0%, PE contracts to 29.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 25, 2026 7:52 AM ET
Data refreshes hourly during market hours. Next update: 8:52 AM
Data refreshes hourly during market hours. Next update: 8:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Allison Swartz
SELL
599 shares
2026-03-04
Allison Swartz
SELL
4657 shares
2026-03-03
Allison Swartz
SELL
2199 shares
2026-03-02
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$105 | 65 BUY |
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
27 analysts |
$410 | 54 HOLD |
|
CI
Cigna Corp |
STRONG BUY
25 analysts |
$341 | 57 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$416 | 58 HOLD |
|
HUM
Humana Inc |
HOLD
26 analysts |
$302 | 60 HOLD |
Advanced PGNY Option Strategies
Professional options setups generated by AI based on today's PGNY price and gamma walls.
